quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·52d
PRRelease
AIM ImmunoTech Inc. logo

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

AIM· AIM ImmunoTech Inc.
Health Care
Original source

Companies

  • AIM
    AIM ImmunoTech Inc.
    Health Care

Related

  • PR7d
    AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
  • PR10d
    AIM ImmunoTech Provides Routine Update on Annual Filings
  • SEC13d
    AIM ImmunoTech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  • SEC13d
    SEC Form 424B5 filed by AIM ImmunoTech Inc.
  • PR14d
    AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
  • SEC27d
    SEC Form 10-K filed by AIM ImmunoTech Inc.
  • PR36d
    Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum
  • PR36d
    AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022